Seven secret ingredients for successfully launching and commercialising a biopharma’s first drug in Europe

After the US, Europe is considered the second most attractive market for serving patient needs while realising commercial value from innovative drugs. However, the 27 EU member states each have their own approaches to pricing and market access – and need tailored commercialisation and go-to-market strategies. Simon-Kucher & Partners analysed over 20 prominent first drug launches by US-based companies in Europe, assessed over 4,500 individual data points from independent launches and conducted interviews with 18 senior executives. Christian Schuler, a Senior Partner at the company, discusses the key value drivers and success factors for US-based biopharma companies when independently launching their first drug in Europe.